Found 4355 articles for: ""
The Gastrointestinal Microbiome and Immune Checkpoint Inhibitors: A Review of Human Interventional Studies Among Melanoma Patients
February 2024 | Volume 23 | Issue 2 | Original Article | 78 | Copyright © February 2024
Immune checkpoint inhibitors (ICI) are widely utilized for the treatment of malignant melanoma. Interestingly, gastrointestinal microbiome composition has emerged as a predictive biomarker of imm...
Read MoreOutcomes for Psoriasis by Self-Identified Racial Groups in Ixekizumab Clinical Trials: A Pooled Analysis
February 2024 | Volume 23 | Issue 2 | Original Article | 17 | Copyright © February 2024
Background: Biologics have shown promising outcomes in psoriasis clinical trials. However, there is a paucity of data exploring the potential differences in outcomes between self...
Read MoreA New Tool to Improve Communication Between Hidradenitis Suppurativa Patients and Health Care Providers
February 2024 | Volume 23 | Issue 2 | Features | 105 | Copyright © February 2024
Background: Hidradenitis suppurativa (HS) patients tend to experience diagnosis delay, misdiagnosis, and embarrassment due to their condition. To address these issues, the Intern...
Read MoreImprovement of Chronic Venous Insufficiency Related Leg Xerosis and Dermatitis With Ceramide-Containing Cleansers and Moisturizers: An Expert-Based Consensus
February 2024 | Volume 23 | Issue 2 | Original Article | 61 | Copyright © February 2024
Introduction: Chronic venous insufficiency (CVI) may lead to sustained elevated pressure (aka venous hypertension) in the dermal venous microcirculation. Risk factors include adv...
Read MoreCysteamine Isobionic-Amide Complex Versus Kligman's Formula for the Treatment of Melasma: Equal Efficacy and Rapid Onset of Action
February 2024 | Volume 23 | Issue 2 | Original Article | 9 | Copyright © February 2024
Background: Modified Kligman's formula (mKF) is the gold standard treatment for melasma; however, its prolonged use is not recommended due to side effects. Cysteamine is a potent...
Read MoreTeledermatology Platforms Usage and Barriers: A Cross-Sectional Analysis of United States-Based Dermatologists Pre- and Post-COVID-19
February 2024 | Volume 23 | Issue 2 | Editorials | e64 | Copyright © February 2024
Background: During the global COVID-19 pandemic, dermatologists increasingly adopted teledermatology to facilitate patient care.Objective: To identi...
Read MoreThe Pediatric Dermatologist's View of Pediatric Vitiligo
February 2024 | Volume 23 | Issue 2 | Editorials | e77 | Copyright © February 2024
Background: No guidelines exist for pediatric vitiligo.Objective: To identify practice patterns of pediatric dermatologists treating vitiligo....
Read MoreImplicit Bias and Clinical Decision Making in Psoriasis Management Among Dermatology Residents: A Feasibility Study
February 2024 | Volume 23 | Issue 2 | Editorials | e73 | Copyright © February 2024
Topical Calcineurin Inhibitors in the Management of Chronic Pruritus in Older Adults: A Research Letter
February 2024 | Volume 23 | Issue 2 | Editorials | e70 | Copyright © February 2024
In this study, we aimed to analyze the literature to date on the utilization of topical calcineurin inhibitors in the management of pruritus among older adults, ages 65 and older. The 16 stu...
Read MoreTips, Trends, and Truths: A Study of Psoriasis Treatment Content on TikTok
February 2024 | Volume 23 | Issue 2 | Editorials | e67 | Copyright © February 2024
Introduction: With more than two billion downloads since its launch, TikTok is the fastest-growing video-sharing platform in the world. Many people turn to TikTok for dermat...
Read MorePsoriasis and Palmoplantar Pustulosis Following Pembrolizumab Therapy Successfully Treated With Topical Tapinarof Cream 1%
February 2024 | Volume 23 | Issue 2 | Case Reports | 103 | Copyright © February 2024
Number of Affected Nails Is the Primary Determinant of Efinaconazole 10% Solution Usage for Onychomycosis
February 2024 | Volume 23 | Issue 2 | Editorials | 110 | Copyright © February 2024
Good adherence to treatment is necessary for the successful treatment of onychomycosis and requires that an appropriate amount of medication be prescribed. Most prescriptions for efinaconazole 10...
Read MoreBlood Monocyte Count Can Predict Early Response to Secukinumab Therapy in Patients With Psoriasis
February 2024 | Volume 23 | Issue 2 | Original Article | 74 | Copyright © February 2024
Early response to treatment with biologics, defined as Psoriasis Area and Severity Index (PASI) of 2 or less six months after initiation of therapy, seems to be associated with more stable psoria...
Read MoreAtypical Dyschromia in Skin of Color
February 2024 | Volume 23 | Issue 2 | Case Reports | 100 | Copyright © February 2024
Dyschromia is a concern for many patients, especially persons of color. Postinflammatory hypopigmentation and depigmentation can affect all skin types; however, it is more apparent in those with ...
Read MoreTargeting the Aryl Hydrocarbon Receptor to Address the Challenges of Atopic Dermatitis
February 2024 | Volume 23 | Issue 2 | Original Article | 23 | Copyright © February 2024
Atopic dermatitis (AD) is a chronic relapsing–remitting disease with a multifactorial etiology involving epidermal barrier and immunologic dysfunction. Topical therapies form the mainstay o...
Read MoreAtopic Dermatitis as a Paradoxical Reaction to Secukinumab in a Patient With Plaque Psoriasis
February 2024 | Volume 23 | Issue 2 | Case Reports | 97 | Copyright © February 2024
Paradoxical reactions to biologic agents used in the treatment of psoriasis are rare but have been reported with tumor necrosis factor (TNF) blockers and, more recently, with interleukin (IL)-17A...
Read MoreSarecycline as a Potential Treatment for Steroid-Induced Rosacea/Perioral Dermatitis: A Case Report
February 2024 | Volume 23 | Issue 2 | Case Reports | e55 | Copyright © February 2024
Neoadjuvant PD-1 Inhibitors: A Tale of Two Cases
February 2024 | Volume 23 | Issue 2 | Case Reports | e57 | Copyright © February 2024
Treatment responses for locally advanced cutaneous squamous cell carcinoma (cSCC) and Merkel cell carcinoma (MCC) are often short lived and are marred with recurrences. The introduction of adjuva...
Read MoreApplications of Bioactive Peptides in Dermatology
January 2024 | Volume 23 | Issue 1 | Features | 1369 | Copyright © January 2024
Comparing the Efficacy and Tolerability of Moderate to Severe Hyperpigmentation and Skin Unevenness
January 2024 | Volume 23 | Issue 1 | Original Article | 1260 | Copyright © January 2024
Media and other results for: ""